NIOX VERO. NIOX VERO device call-to-action. Order NIOX VERO. Contact us today to order your FeNO by NIOX device and other consumables. Order Now. Services and Markets Act (Financial Promotion) Order (as that shares in Aerocrine can be sold at a price acceptable to. The total value of the Offer, based on ,, shares in Aerocrine, amounts to SEK 1,,,[1] The Offer Price corresponds to a.

Author: Arashikasa Kazrashura
Country: Gabon
Language: English (Spanish)
Genre: Finance
Published (Last): 18 November 2008
Pages: 398
PDF File Size: 20.35 Mb
ePub File Size: 9.96 Mb
ISBN: 717-4-77261-616-8
Downloads: 63363
Price: Free* [*Free Regsitration Required]
Uploader: Mimuro

FeNO by NIOX® | FeNO KNOWHOW | Outside the US, UK and Germany

Accurately assess and monitor airway inflammation While airway inflammation is known to be the major underlying characteristic of asthma, there are few methods of measuring it. Patient enough to hold good investments at least until the market is willing to recognise its full potential.

The structural growth component can be driven by secular market trends, technological leadership, a superior business model or any type of durable competitive advantage. Yet price and value are two very distinct concepts. Though, any worst-case scenario is often more consequential than the forecast itself.

Aerocrine AB B (XSTO:AERO B) – Share price – Chart

Leadership Our Leadership rating represents an assessment of the ability of the board and executive team to lead the company in the best interests of the shareholders. In addition to our cash flow-based analysis we often use a comparables approach to make snapshot comparisons between similar companies within industries or to measure value versus sector or market prives.

Forward-looking statements inherently involve both anv and unknown risks and uncertainties as they depend on future events and circumstances. The subscription price is SEK 0.

AEROCRINE AB strengthens its financial position by a rights issue of approximately SEK 445 million

However, based on current forecasts, and absent a strategic collaboration or larger than expected growth in revenue, existing cash is sufficient to finance the current scope of operations until approximately the end of the second quarter ; and sufficient cash to meet the conditions of the credit agreement at least until the end of December Do you want to continue?

This press release does not constitute an extension into the United States or any other jurisdiction of the Offer mentioned in this press release.

Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.


Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June The effect of any such acceleration would be that Aerocrine would be required to pay a prepayments penalty equal to 50 per cent of the amount being prepaid.

Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from. Companies need highly qualified management to execute a plan to create long-term shareholder value, even if it comes at the expense of short-term results. For more information, please contact: Failure to comply with this instruction may result in a violation of applicable securities laws.

Sales figure represents last 12 months as of March 31, These quantitative scores are grouped into five categories, each assessed on a number of quantitative and qualitative questions structured into different sub-categories. The information was submitted for publication at About Us Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases.

Profitability Our Profitability rating represents an assessment of how effective a company has historically utilised its capital to generate profit. Circassia is offering SEK 2.

Any invitation to the persons concerned to subscribe for shares in Aerocrine will only be made through the prospectus that Aerocrine estimates to publish on or around 12 January In total, subscription undertakings and underwriting commitments correspond to more than 75 percent of the full rights issue amount under certain conditions.

This growth is expected to be achieved while the company is continuing to focus on overall expense control and selectively pursue growth opportunities with targeted funding.

Aerocrine AB B (XSTO:AERO B) – Share price – Overview | AJ Bell Youinvest

A company that does not grow may be a good short-term investment, but is usually unwise in the long term. Our Leadership rating represents an assessment of the ability of the board and executive team to lead the company in the best interests of the shareholders. Circassia has not received any other non-public information that could reasonably be expected to affect the price of the Aerocrine share in connection with the review.

A prospectus relating to the rights issue will be made public before the commencement of the subscription period. To date, over 18 million tests have been performed using a NIOX device, supporting clinicians to enhance the accuracy of diagnosis and better-personalized control. You are solely responsible for interactions with such third-party website s.


Circassia has reserved the right to waive these and other conditions for completion of the Offer. The Bull case serves the sell discipline in order to identify a potential exit. Additional shares in Aerocrine may be issued following this point in time as a result of exercise of outstanding personnel stock options and warrants in Aerocrine, and any such additional shares shall be included in the Offer.

The acceptance period of the Offer is expected to commence on May 19, and expire on June 11,subject to any extensions. The Information was submitted for publication on May 15, at At Redeye, margin of safety is heavily conscious of what could go wrong, not what the discount is to fair value.

But we also try to use specific information about the case to adjust the baseline prediction, if there are particular reasons to expect the optimistic bias to be more or less pronounced in this project than in others of the same type. Basic aspects of exhaled nitric oxide.

The decision on the rights issue is subject to approval by an Extraordinary General Meeting that is planned to take place on Wednesday 7 January Circassia Ltd March Identify important events short and longer term in duration that could be catalysts to cause the stock to perform significantly different than its peers or the broader market, i.

In addition, the company will leverage the VERO product and software platform to finalize development of a home-treatment monitoring device in accordance with the recently published guidelines for home medical devices by the FDA. This means that in case Circassia completes the Offer, even if such completion is made at a lower acceptance level than more than 90 per cent of the shares, the payment under the credit agreement may be accelerated and the prepayment penalty may become due and payable.

Proceeds from the rights offering will be used to invest in four strategic growth pillars and enable the company to achieve several very valuable inflection points such as: Medical Devices Evidence and Research. Catalyst Potential is a tool for our analyst to flag specific catalysts that may drive the share price.